FIELD: pharmaceuticals.
SUBSTANCE: invention relates to an urea compound having an LPA1 receptor antagonist effect represented by formula [I], or a pharmaceutically acceptable salt or hydrate thereof. The meanings of the radicals in formula [I] are defined in the claims. Also the following is proposed: a medicinal product for the prevention or treatment of a disease caused by LPA1, containing a compound of formula [I], in particular for the prevention or treatment of systemic scleroderma.
EFFECT: compound represented by formula [I] has an antagonistic effect on the LPA1 receptor and can be used to prepare a drug effective for the prevention or treatment of diseases associated with fibrosis such as systemic scleroderma.
15 cl, 210 tbl, 632 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF PRODUCING PYRIPYROPENE DERIVATIVES AND INTERMEDIATE PRODUCTS FOR PRODUCTION THEREOF | 2008 |
|
RU2494101C2 |
| OXASPIRO DERIVATIVE SUBSTITUTED AT AZABICYCLIC RING, A METHOD OF ITS PRODUCTION AND ITS MEDICAL USE | 2021 |
|
RU2800296C1 |
| COMPOUNDING, WHICH INHIBITES ACTIVITY OF BTK AND/OR JAK3 KINASES | 2014 |
|
RU2650512C2 |
| 3-AMINOPYRIDINES AS GPBAR1 AGONISTS | 2012 |
|
RU2594886C2 |
| DERIVATIVE OF PYRIMIDINE AND A FIVE-MEMBERED NITROGEN-CONTAINING HETEROCYCLE, METHOD FOR PRODUCTION AND MEDICAL APPLICATIONS THEREOF | 2019 |
|
RU2775229C1 |
| OXASPIRO DERIVATIVE, A METHOD FOR PRODUCTION THEREOF AND USE THEREOF IN MEDICINES | 2016 |
|
RU2733373C2 |
| TYPE 1 DIACYLGLYCEROL O-ACYLTRANSFERASE ENZYME INHIBITORS | 2008 |
|
RU2497816C2 |
| DERIVATIVES OF 6-AMINO QUINAZOLINE OR 3-CYANOQUINOLINE, METHODS OF THEIR PRODUCTION AND THEIR APPLICATION AS INHIBITORS OF RECEPTOR TYROZINE KINASES EGFR OR HER-2 | 2010 |
|
RU2536102C2 |
| SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | 2019 |
|
RU2812726C2 |
| BENZAMIDE COMPOUNDS | 2019 |
|
RU2801647C2 |
